Department of Ophthalmology, Wake Forest University Eye Centre, Winston Salem, North Carolina 27101, USA. skurup@wfubmc.edu
PURPOSE: To evaluate the therapeutic effect of intravitreal bevacizumab in patients with uveitis-associated choroidal/retinal neovascularization. METHODS: Two female patients (40 years, 15 years) with posterior uveitis, (one presumed ocular sarcoidosis, one lupus) were evaluated for neovascularization of the posterior segment. Both patients were given a single dose of 1.25 mg intravitreal bevacizumab. RESULTS: Significant anatomical and functional recovery was evident in both patients within a few weeks. CONCLUSION: In selected uveitic patients, bevacizumab may be an option for managing neovascularization.